NAUTILUS BIOTECHNOLOGY INC's ticker is NAUT and the CUSIP is 63909J108. A total of 79 filers reported holding NAUTILUS BIOTECHNOLOGY INC in Q2 2024. The put-call ratio across all filers is 0.17 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,344,705 | -4.7% | 574,844 | +19.8% | 0.00% | – |
| Q1 2024 | $1,411,011 | +17.6% | 479,936 | +19.7% | 0.00% | – |
| Q4 2023 | $1,200,167 | +56.4% | 401,025 | +65.1% | 0.00% | – |
| Q3 2023 | $767,324 | +149.1% | 242,952 | +203.8% | 0.00% | – |
| Q2 2023 | $307,978 | +313.8% | 79,961 | +197.6% | 0.00% | – |
| Q1 2023 | $74,430 | – | 26,870 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| AH Equity Partners Bio II, L.L.C. | 16,298,006 | $70,733,000 | 40.75% |
| Madrona Venture Group, LLC | 6,020,770 | $26,130,000 | 7.74% |
| AH Equity Partners LSV II, L.L.C. | 1,355,911 | $5,885,000 | 4.24% |
| Ally Bridge Group (NY) LLC | 1,080,566 | $4,690,000 | 3.48% |
| ArchPoint Investors | 1,449,551 | $6,291,000 | 2.17% |
| Tikvah Management LLC | 1,488,895 | $6,462,000 | 2.07% |
| Bain Capital Life Sciences Investors, LLC | 2,000,000 | $8,680,000 | 0.84% |
| Perceptive Advisors | 9,111,151 | $39,542,000 | 0.79% |
| SPHERA FUNDS MANAGEMENT LTD. | 840,000 | $3,646,000 | 0.52% |
| Decheng Capital Management III (Cayman), LLC | 300,000 | $1,302,000 | 0.40% |